Hepcvel is an antiviral medication used to treat chronic Hepatitis C virus (HCV) infection. It combines two active ingredients: Sofosbuvir (400 mg) and Velpatasvir (100 mg). Sofosbuvir is a nucleotide polymerase inhibitor that blocks the NS5B protein, essential for viral replication. Velpatasvir is an NS5A inhibitor that interferes with another protein necessary for the virus to multiply. Together, they effectively reduce and eliminate HCV from the bloodstream.
Hepcvel is effective against all six major HCV genotypes, making it a versatile treatment option. The standard regimen involves taking one tablet orally once daily for 12 weeks. In patients with decompensated cirrhosis, it may be used in combination with ribavirin. Adherence to the prescribed course is crucial to achieve optimal outcomes.
Common side effects include headache, fatigue, nausea, and insomnia. Most are mild and transient. However, patients should inform their healthcare provider of any other medications they are taking to avoid potential interactions. Regular monitoring during treatment ensures safety and effectiveness.
Hepcvel has significantly improved HCV treatment outcomes, offering a high cure rate with a convenient, once-daily oral regimen. Its broad-spectrum efficacy simplifies therapy across diverse patient populations. Consultation with a healthcare professional is essential to determine the most appropriate treatment plan.
Reviews
There are no reviews yet.